Soluble fibers and resistant starch ameliorate disease activity in interleukin-10-deficient mice with inflammatory bowel disease

Journal of Nutrition

Volumn 141, Issue 7, 2011, Pages 1318-1325

  Bassaganya Riera, Josep ^a   DiGuardo, Margaret ^b   Viladomiu, Monica ^a   de Horna, Anibal ^a   Sanchez, Sandra ^a   Einerhand, Alexandra W C ^c   Sanders, Lisa ^c   Hontecillas, Raquel ^a  

^a VIRGINIA BIOINFORMATICS INSTITUTE   (United States)

^b Nutrition Therapeutics Inc   (United States)

^c Tate and Lyle Speciality Sweeteners   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GAMMA INTERFERON; INTERLEUKIN 10; INULIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; POLYDEXTROSE; PULLULAN; RESISTANT STARCH 75; STARCH; SUPPRESSOR OF CYTOKINE SIGNALING 3; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CD4+ T LYMPHOCYTE; CELL ISOLATION; COLON; CONTROLLED STUDY; CORN; CYTOKINE PRODUCTION; DIET SUPPLEMENTATION; DIETARY FIBER; DISEASE ACTIVITY; DUODENUM; ENTERITIS; FEMALE; GENE EXPRESSION REGULATION; HISTOLOGY; ILEUM; IMMUNOMODULATION; JEJUNUM; KNOCKOUT MOUSE; LYMPHOCYTE COUNT; MALE; MESENTERY LYMPH NODE; MONONUCLEAR CELL; MOUSE; NONHUMAN; PEYER PATCH; PROTEIN EXPRESSION; PROTEIN SYNTHESIS INHIBITION; REGULATORY T LYMPHOCYTE; SIGNAL TRANSDUCTION; SOLUBLE CORN FIBER; SPLEEN; UPREGULATION; WILD TYPE;

ANIMALS; CD4-POSITIVE T-LYMPHOCYTES; COLON; CYTOKINES; DIETARY FIBER; FEMALE; ILEUM; INFLAMMATORY BOWEL DISEASES; INTERLEUKIN-10; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; PEYER'S PATCHES; PPAR GAMMA; SOLUBILITY; SPLEEN; STARCH; SUPPRESSOR OF CYTOKINE SIGNALING PROTEINS; T-LYMPHOCYTES, REGULATORY;

MUS; ZEA MAYS;

EID: 79960316106     PISSN: 00223166     EISSN: 15416100     Source Type: Journal    
DOI: 10.3945/jn.111.139022     Document Type: Article

References (41)

1. Strober W, Fuss IJ, Blumberg RS. The immunology of mucosal models of inflammation. Annu Rev Immunol. 2002;20:495-549.
2. Xavier RJ, Podolsky DK. Unravelling the pathogenesis of inflammatory bowel disease. Nature. 2007;448:427-34.
3. Camilleri M. GI clinical research 2002-2003: the year in review. Clin Gastroenterol Hepatol. 2003;1:415-20.
4. Lichtenstein GR, Abreu M, Present D. Recent advances in the treatment of Crohn's colitis. Killingworth (CT): The Center for Health Care Education, LLC; 2003.
5. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel JF, Egan LJ. Risk factors for opportunistic infections in patients with inflammatory bowel disease. Gastroenterology. 2008;134:929-36.
6. Clarke JO, Mullin GE. A review of complementary and alternative approaches to immunomodulation. Nutr Clin Pract. 2008;23:49-62.
7. Kong SC, Hurlstone DP, Pocock CY, Walkington LA, Farquharson NR, Bramble MG, McAlindon ME, Sanders DS. The Incidence of selfprescribed oral complementary and alternative medicine use by patients with gastrointestinal diseases. J Clin Gastroenterol. 2005;39:138-41.
8. Leenen CH, Dieleman LA. Inulin and oligofructose in chronic inflammatory bowel disease. J Nutr. 2007;137:S2572-5.
9. Maslowski KM, Vieira AT, Ng A, Kranich J, Sierro F, Yu D, Schilter HC, Rolph MS, Mackay F, et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461: 1282-6.
10. Reeves PG, Nielsen FH, Fahey GC Jr. AIN-93 purified diets for laboratory rodents: final report of the American Institute of Nutrition ad hoc writing committee on the reformulation of the AIN-76A rodent diet. J Nutr. 1993;123:1939-51.
11. Bassaganya-Riera J, Reynolds K, Martino-Catt S, Cui Y, Hennighausen L, Gonzalez F, Rohrer J, Benninghoff AU, Hontecillas R. Activation of PPAR gamma and delta by conjugated linoleic acid mediates protection from experimental inflammatory bowel disease. Gastroenterology. 2004; 127:777-91.
12. Maathuis A, Hoffman A, Evans A, Sanders L, Venema K. The effect of the undigested fraction of maize products on the activity and composition of the microbiota determined in a dynamic in vitro model of the human proximal large intestine. J Am Coll Nutr. 2009;28:657-66.
13. Saubermann LJ, Beck P, De Jong YP, Pitman RS, Ryan MS, Kim HS, Exley M, Snapper S, Balk SP, et al. Activation of natural killer T cells by alpha-galactosylceramide in the presence of CD1d provides protection against colitis in mice. Gastroenterology. 2000;119:119-28.
14. Bassaganya-Riera J, DiGuardo M, Climent M, Vives C, Carbo A, Jouni ZE, Einerhand AWC, O'Shea M, Hontecillas R. Activation of PPAR gamma and delta by dietary punicic acid ameliorates intestinal inflammation in mice. Br J Nutr. In press 2011.
15. Hontecillas R, Bassaganya-Riera J. Peroxisome proliferator-activated receptor gamma is required for regulatory CD4+ T cell-mediated protection against colitis. J Immunol. 2007;178:2940-9.
16. Young GP, Hu Y, Le Leu RK, Nyskohus L. Dietary fibre and colorectal cancer: a model for environment-gene interactions. Mol Nutr Food Res. 2005;49:571-84.
17. Topping DL, Clifton PM. Short-chain fatty acids and human colonic function: roles of resistant starch and nonstarch polysaccharides. Physiol Rev. 2001;81:1031-64.
18. Jacobasch G, Schmiedl D, Kruschewski M, Schmehl K. Dietary resistant starch and chronic inflammatory bowel diseases. Int J Colorectal Dis. 1999;14:201-11.
19. Moreau NM, Martin LJ, Toquet CS, Laboisse CL, Nguyen PG, Siliart BS, Dumon HJ, Champ MM. Restoration of the integrity of rat caecocolonic mucosa by resistant starch, but not by fructo-oligosaccharides, in dextran sulfate sodium-induced experimental colitis. Br J Nutr. 2003;90:75-85.
20. Simpson EJ, Chapman MA, Dawson J, Berry D, Macdonald IA, Cole A. In vivo measurement of colonic butyrate metabolism in patients with quiescent ulcerative colitis. Gut. 2000;46:73-7.
21. Maathuis A, Hoffman A, Evans A, Sanders L, Venema K. The effect of the undigested fraction of maize products on the activity and composition of the microbiota determined in a dynamic in vitro model of the human proximal large intestine. J Am Coll Nutr. 2009;28:657-66.
22. Weaver CM, Martin BR, Story JA, Hutchinson I, Sanders L. Novel fibers increase bone calcium content and strength beyond efficiency of large intestine fermentation. J Agric Food Chem. Epub 2010 Aug 2.
23. Galvez J, Rodriguez-Cabezas ME, Zarzuelo A. Effects of dietary fiber on inflammatory bowel disease. Mol Nutr Food Res. 2005;49:601-8.
24. Toden S, Bird AR, Topping DL, Conlon MA. Dose-dependent reduction of dietary protein-induced colonocyte DNA damage by resistant starch in rats correlates more highly with caecal butyrate than with other short chain fatty acids. Cancer Biol Ther. 2007;6:253-8.
25. Wachtershauser A, Loitsch SM, Stein J. PPAR-gamma is selectively upregulated in Caco-2 cells by butyrate. Biochem Biophys Res Commun. 2000;272:380-5.
26. Schwab M, Reynders V, Loitsch S, Steinhilber D, Stein J, Schroder O. Involvement of different nuclear hormone receptors in butyrate-mediated inhibition of inducible NF kappa B signalling. Mol Immunol. 2007;44: 3625-32.
27. Atreya I, Atreya R, Neurath MF. NF-kappaB in inflammatory bowel disease. J Intern Med. 2008;263:591-6.
28. Coakley M, Ross RP, Nordgren M, Fitzgerald G, Devery R, Stanton C. Conjugated linoleic acid biosynthesis by human-derived Bifidobacterium species. J Appl Microbiol. 2003;94:138-45.
29. Berg DJ, Zhang J, Lauricella DM, Moore SA. Il-10 is a central regulator of cyclooxygenase-2 expression and prostaglandin production. J Immunol. 2001;166:2674-80.
30. Kucharzik T, Lugering N, Pauels HG, Domschke W, Stoll R. IL-4, IL-10 and IL-13 down-regulate monocyte-chemoattracting protein-1 (MCP-1) production in activated intestinal epithelial cells. Clin Exp Immunol. 1998;111:152-7.
31. Shi D, Das J, Das G. Inflammatory bowel disease requires the interplay between innate and adaptive immune signals. Cell Res. 2006;16:70-4.
32. Noti M, Corazza N, Mueller C, Berger B, Brunner T. TNF suppresses acute intestinal inflammation by inducing local glucocorticoid synthesis. J Exp Med. 2010;207:1057-66.
33. Andoh A, ShioyaM, Nishida A, Bamba S, Tsujikawa T, Kim-Mitsuyama S, Fujiyama Y. Expression of IL-24, an activator of the JAK1/STAT3/SOCS3 cascade, is enhanced in inflammatory bowel disease. J Immunol. 2009;183: 687-95.
34. Suzuki A, Hanada T, Mitsuyama K, Yoshida T, Kamizono S, Hoshino T, Kubo M, Yamashita A, Okabe M, et al. CIS3/SOCS3/SSI3 plays a negative regulatory role in STAT3 activation and intestinal inflammation. J Exp Med. 2001;193:471-81.
35. Yasukawa H, Sasaki A, Yoshimura A. Negative regulation of cytokine signaling pathways. Annu Rev Immunol. 2000;18:143-64.
36. Valencia X, Yarboro C, Illei G, Lipsky PE. Deficient CD4+CD25high T regulatory cell function in patients with active systemic lupus erythematosus. J Immunol. 2007;178:2579-88.
37. Coombes JL, Robinson NJ, Maloy KJ, Uhlig HH, Powrie F. Regulatory T cells and intestinal homeostasis. Immunol Rev. 2005;204: 184-94.
38. Brimnes J, Allez M, Dotan I, Shao L, Nakazawa A, Mayer L. Defects in CD8+ Regulatory T Cells in the Lamina Propria of Patients with Inflammatory Bowel Disease. J Immunol. 2005;174:5814-22.
39. Guri AJ, Mohapatra SK, Horne WT II, Hontecillas R, Bassaganya-Riera J. The role of T cell PPAR gamma in mice with experimental inflammatory bowel disease. BMC Gastroenterol. 2010;10:60.
40. Guri AJ, Evans NP, Hontecillas R, Bassaganya-Riera J. T cell PPAR gamma is required for the anti-inflammatory efficacy of abscisic acid against experimental IBD. J Nutr Biochem. Epub 2010 Nov 24.
41. Schwab M, Reynders V, Ulrich S, Zahn N, Stein J, Schroder O. PPARgamma is a key target of butyrate-induced caspase-3 activation in the colorectal cancer cell line Caco-2. Apoptosis. 2006;11: 1801-11.